I first reviewed Build-A-Bear Workshop (NYSE: BBW ) back in January. I gave the company a “Buy” rating, as I liked that this well-known retail brand was growing revenues and expanding both their physical and digital presence. BBW was rewarding investors with dividends, shareAnalyst’s Disclosure:I/we have a beneficial long position in the shares of BBW either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation ...

Core Insights - ONWARD Medical N.V. has successfully transitioned to a commercial organization, achieving significant milestones in the first quarter of 2025, particularly with the launch of the ARC-EX System and positive user feedback [1][12] Commercial Traction - The company met its Q1 objective for the initial phase of the US launch of the ARC-EX System, hiring and training a field organization, establishing sales processes, and selling ten systems [2][7] - Strong early demand indicates the company expects to meet its first half sales target of approximately 30 systems [2][12] - ONWARD secured access to US government online procurement platforms, allowing Veterans Affairs and other government buyers to purchase the ARC-EX System [3] Technology Advancement - The first human implant of the ARC-IM Lumbar Lead was announced, designed for optimal placement in the lumbar region to restore mobility [4] - The company received two grants for early clinical feasibility studies using the ARC-IM System to assist individuals with Parkinson's disease, totaling USD 2.5 million [5] - Preparations are underway for the Empower BP global pivotal study to assess the ARC-IM System's efficacy in addressing blood pressure instability after spinal cord injury, pending FDA approval [6][13] Scientific Leadership - The Pathfinder2 study results published in a peer-reviewed journal demonstrated that sustained access to ARC-EX Therapy can lead to continued functional improvements over one year [10] - The company announced successful implants of its ARC-BCI technology, reinforcing its leadership in developing brain-computer interface solutions for spinal cord injury [8][9] Financial Highlights - The company reported EUR 0.4 million in revenue for Q1 2025 and ended the quarter with net cash of EUR 50.5 million [11] - A sponsored Level 1 American Depositary Receipt (ADR) program was established to facilitate US investor participation [11] Outlook - ONWARD anticipates FDA clearance for the ARC-EX System for home use and CE Mark authorization for marketing in Europe [13] - The company plans to continue additional implants of the ARC-IM System and ARC-BCI to explore further indications in spinal cord injury and Parkinson's disease [13]

Core Points - Aalberts has repurchased 2,500 shares from June 9 to June 13, 2025, for a total of EUR 78,285.24, averaging EUR 31.31 per share [1] - The total shares repurchased under the buyback program up to June 13, 2025, is 1,842,869, amounting to EUR 54,988,223 [2] - The share buyback program is part of a larger initiative announced on February 27, 2025, with a total budget of EUR 75 million, set to conclude by October 24, 2025 [1][2] - The buyback is conducted within the authority granted by the AGM on May 23, 2024, and adheres to the Market Abuse Regulation and safe harbour parameters [3] Summary by Categories Share Buyback Program - The share buyback program commenced on February 28, 2025, and is intended to cancel the repurchased shares [1] - An intermediary has been engaged to facilitate the repurchase in the open market, independent of Aalberts [2] Financial Details - The average price per share repurchased during the recent period was EUR 31.31, with a total expenditure of EUR 78,285.24 for 2,500 shares [1] - Cumulatively, the company has spent EUR 54,988,223 on repurchasing shares as of June 13, 2025 [2] Regulatory Compliance - The buyback program is executed in compliance with the regulations set forth by the Market Abuse Regulation and the Commission Delegated Regulation [3]

Core Insights - ONWARD Medical N.V. has successfully transitioned to a commercial organization, achieving significant milestones in the first quarter of 2025, particularly with the ARC-EX System, which has received strong initial demand and positive user feedback [1][12]. Commercial Traction - The company met its Q1 objective for the initial phase of the US launch of the ARC-EX System, successfully hiring and training a field organization, establishing sales processes, and selling ten systems [2][7]. - ONWARD anticipates meeting its first half sales target of approximately 30 systems, indicating a strong outlook for 2025 [2][12]. - The company secured access to prominent US government online procurement platforms, allowing Veterans Affairs and other government buyers to purchase the ARC-EX System [3]. Technology Advancement - ONWARD announced the first human implant of its ARC-IM Lumbar Lead, designed for optimal placement in the lumbar region to restore standing and lower limb mobility [4]. - The company received two grants to support early clinical feasibility studies using the ARC-IM System for addressing mobility challenges in Parkinson's disease, including a USD 1M grant from the Michael J. Fox Foundation and a USD 1.5M grant from the US Department of Defense [5]. - The company is preparing to initiate the Empower BP global pivotal study to assess the safety and efficacy of the ARC-IM System for blood pressure instability after spinal cord injury, pending FDA approval [6][13]. Scientific Leadership - The Pathfinder2 study results published in a peer-reviewed journal demonstrated that sustained access to ARC-EX Therapy can lead to continued functional improvements in individuals with spinal cord injuries [10]. - The company announced the successful 4th and 5th implants of its ARC-BCI technology, reinforcing its leadership in developing brain-computer interface solutions for movement restoration [8]. Financial Highlights - For Q1 2025, ONWARD reported EUR 0.4M in revenue and ended the quarter with net cash of EUR 50.5M [11]. - The company established a sponsored Level 1 American Depositary Receipt (ADR) program to facilitate US investor participation in its growth [11]. Outlook - ONWARD expects to receive FDA clearance for the ARC-EX System for home use and anticipates CE Mark authorization for marketing in Europe [13].

Paysafe Limited (NYSE: PSFE ) recently sold a significant amount of assets, which could enhance future financial statements. Besides, the company is investing a large amount of money in transformation efforts. In my view, these efforts will most likely bring FCF marginBased in Europe, I am an independent investor with more than a decade of experience. I research cash flow statements and unlevered free cash flow figures. My articles may include a number of assumptions about the future free cash flow of compa ...

An Amazon worker moves boxes on Amazon Prime Day in the East Village of New York City, July 11, 2023.Amazon is extending its Prime Day discount bonanza, announcing that the annual sale will run four days this year.The 96-hour event will start at 12:01 a.m. PT on July 8, and continue through July 11, Amazon said in a release.For the first time, the company will roll out themed "deal drops" that change daily and are available "while supplies last." Amazon has in recent years toyed with adding more limited-run ...

Les Ulis, June 17, 2025 at 7:00 a.m. ANNUAL RESULTS 2024-25 FOR THE LEXIBOOK GROUP: ANNUAL REVENUE AT €74.0M (+26.3%). EBIT AND NET INCOME UP, AT €8.1M AND €7.4M RESPECTIVELY, THANKS TO AN EXCEPTIONAL COMBINATION OF POSITIVE FACTORS. UNCERTAIN OUTLOOK FOR THE 2025-26 FISCAL YEAR DUE TO HIGH UNPREDICTABILITY REGARDING U.S. CUSTOMS DUTIES, FREIGHT COSTS, EXCHANGE RATES, AND CONSUMPTION. Annual Revenue: A record fiscal year after 5 consecutive years of growth. For the full fiscal year, which had already grown ...

May for LHV was characterised by the rapid growth of the loan portfolio. Profitability was impacted by the ongoing decline in interest rates and the partial reversal of previous impairments. LHV Group’s consolidated loan portfolio grew by EUR 104 million in May. At the same time, the total volume of deposits decreased by EUR 34 million. The volume of funds managed by LHV decreased by EUR 11 million over the month. In May, 6.7 million payments related to financial intermediaries were made. In May, AS LHV Gro ...

Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress Continued progress in advancing varoglutamstat in kidney disease based on encouraging data and expansion of IP portfolioVaroglutamstat’s pre-clinical dataset showing synergistic effect in combination with an SGLT-2 inhibitor in different treatment regimensNovel composition of matter patent for varoglutamstat granted after accelerated review in the U.S.; patent term to provide exclusivity through 2044 with subsequent opportunity fo ...

Core Insights - A global study by IBM reveals that while 81% of CMOs recognize AI's strategic importance, 84% face challenges due to fragmented operations [2][3] - The study indicates a significant execution gap in translating AI strategies into tangible outcomes, with 54% of respondents underestimating operational complexity [2][7] Group 1: AI Integration and Challenges - 65% of CMOs agree that AI-literate talent is essential for achieving high-priority objectives, yet only 21% believe they possess the necessary talent for the next two years [8] - 69% of surveyed CMOs acknowledge that new privacy regulations will necessitate a reevaluation of their data strategy [8] - Only 22% of organizations have established clear guidelines for AI in automated decision-making, indicating a need for improved frameworks [7][8] Group 2: Operational Efficiency and Collaboration - 64% of CMOs are now responsible for profitability, while 58% are accountable for revenue growth, highlighting the need for better technology integration [3][7] - Respondents facing internal collaboration challenges reported a 12% revenue growth in 2024, compared to 13% for higher-performing peers, suggesting a potential $140 million upside for an average $14 billion revenue base [3] - Just under a quarter (24%) of respondents have technology platforms that support consistent cross-functional collaboration, and only 44% have integrated systems for demand planning and fulfillment [8] Group 3: Cultural and Operational Shifts - Only 23% of CMOs feel employees are prepared for the cultural and operational shifts brought by AI, with 67% viewing reshaping culture as their responsibility [3] - 62% of respondents report that the pace of change creates tensions between demand and operations functions, indicating a need for better alignment [8] - The study suggests that fully aligning marketing, sales, and operations could unlock a 20% increase in organizational revenue [8]